Anthera Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Anthera Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Anthera Pharmaceuticals: 16 sponsored US clinical trials, none currently recruiting.
Anthera Pharmaceuticals sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 7 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Exocrine Pancreatic Insufficiency, with 3 trials.
Top-decile sponsor footprint
Anthera Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
EASY: Extended Access to Sollpura Over Years
NCT02823964
SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
NCT02734810
SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis
NCT02279498
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.
NCT01522196
Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects
NCT01359605
A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function
NCT01359579
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
NCT01305746
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
NCT01162681
VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
NCT01130246
Phase III ALTU-135 CP Safety Trial
NCT00500084
PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease
NCT00525954
Open-Label Phase III Long-Term Safety Trial of Liprotamase
NCT00449904
Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
NCT00449878
PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease
NCT00455546
IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome
NCT00434473
Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency
NCT00095732
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Therapeutic Areas
How the Anthera Pharmaceuticals archive is shaped
16 indexed studies, none listed as recruiting (0% open); 12 completed (75%).
Phase mix: 7 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Exocrine Pancreatic Insufficiency (3 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Anthera Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Anthera Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- A.T. Still University of Health Sciences · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Anthera Pharmaceuticals page
16 registered trials is a research-attention snapshot, not an endorsement of Anthera Pharmaceuticals or any single study.
- None of Anthera Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Exocrine Pancreatic Insufficiency is the condition Anthera Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Exocrine Pancreatic Insufficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Anthera Pharmaceuticals pipeline card: 16 registered trials from official public datasets.Report a data error.